Iliac crest marrow versus proximal tibia Avitus bone graft for foot and ankle procedures
Official title: Comparison of Iliac Crest Marrow vs. Proximal Tibia Avitus® Bone Graft
Run by Mayo Clinic · NCT07434505 · Data updated 2026-11-12
This will test whether bone graft taken from the proximal tibia with the Avitus device works as well as iliac crest bone marrow for adults needing autograft during foot or ankle fusion or nonunion surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Jacksonville, Florida) |
| Status | Recruiting |
| Started | November 6, 2025 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | February 25, 2026 |
| Trial ID | NCT07434505 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–69 who are skeletally mature, speak English or have a translator, and are scheduled for indicated foot or ankle fusion or nonunion surgery with an indication for both proximal tibia autograft and iliac crest bone marrow aspiration and sufficient harvest volume are ideal candidates.
✕Probably not a fit
Patients aged 70 or older, those with osteopenia/osteoporosis, prior bilateral iliac wing trauma or bilateral total knee arthroplasties, insufficient harvest volume, or who are not undergoing the specified procedures are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults scheduled for ankle, hindfoot, or complex mid/forefoot fusion or treatment of nonunions who require autograft will be enrolled at Mayo Clinic Jacksonville. Each participant will have marrow or graft material obtained from the iliac crest and from the proximal tibia using the Avitus Bone Harvester so comparative samples can be collected. Samples will be compared for harvest volume and cellular/material properties, and patients will be followed for immediate procedural outcomes and donor-site morbidity. Preoperative radiographs of the knee and pelvis will confirm suitability of harvest sites.
Why it matters
Potential benefit: If successful, the Avitus proximal tibia harvest could provide similar graft material with less donor-site pain and fewer complications than traditional iliac crest harvest.
How similar studies have gone: Prior reports suggest proximal tibia harvest can yield comparable cell counts to iliac crest marrow in some settings, but device-specific head-to-head data for the Avitus harvester are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient must be 18 years of age or older. * Patient must be able and willing to sign the IRB approved informed consent. * Patient must consent to preoperative knee and pelvis radiographs to confirm no issue at harvest location. * Patient has indication for autograft bone harvest (undergoing any ankle or hindfoot fusion, complex mid and forefoot fusions requiring graft supplementation, treatment of fuse and fracture nonunions) * Patient is indicated for proximal tibia autograft harvest and iliac crest BMA (e.g. no hx bilateral TKAs or previous iliac wing trauma bilaterally). * Patient is skeletally "mature" and presents with no concern for osteopenia/osteoporosis. * Patient has sufficient volume of harvest material for study inclusion (minimum of 10 ml of cancellous bone graft plus 10 ml fluid pressed out from cancellous bone portion) * Patient must speak English or have access to sufficient translator. Exclusion Criteria: * Patient is 70 yrs of age or older. * Patient is unwilling or unable to give consent or comply with study protocol. * Patient has any condition, which in the judgement of the Investigator, places the patient at undue risk or interferes with the study. * Patient has mental or neurological disorder that will not allow for proper informed consent. * Patient is known to be pregnant or breastfeeding. * Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and/or anticipated to be non-compliant). * Patient has any condition, which in the judgement of the Investigator, may chemically skew bone marrow. This may include but is not limited to the following: * Cancer * Undergoing chemotherapy radiation, * Bone marrow transplant * Infection at the donor sites * Organ transplant on antirejection meds * Usage of anti-rheumatologic drugs * Chronic steroid usage * Anemia * Myelodysplastic Syndromes * Patient presents with arthritis of the knee and may require knee replacement within the next 12 months.
Where it's running
-
Mayo Clinic
Jacksonville, Florida, United States Recruiting
Study contacts
- Principal investigator: Edward T. Haupt, MD — Mayo Clinic
- Study coordinator: Edward T Haupt, M.D.
- Email: Haupt.Edward@mayo.edu
- Phone: 904-953-2496
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing bone graft options for ACL reconstruction
This study tests which type of bone graft, either a patient's own bone or a special putty, works better for people getting surgery to fix a torn ACL.
-
Using acellular collagen matrix to aid wound closure after bone grafting for dental implants
This study tests whether using a special collagen material can help wounds heal better after bone grafting for dental implants.
-
Evaluation of AdvanCore Bone Graft for Bone Healing
This study is testing if the AdvanCore bone graft can help adults with serious bone defects heal better over a year.
-
Comparing new bone graft materials for preserving jawbone after tooth extraction
This study is testing a new bone graft material to see if it can better preserve jawbone after tooth extractions compared to a standard option, helping people who need implants in the future.
-
Graft-versus-host disease after stem cell transplant: testing LBP-MARCO with ruxolitinib
We are testing whether combining LBP-MARCO with ruxolitinib is safe for adults with GVHD after a stem cell transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.